|
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical research trials and Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy. Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy clinical trial. Human subjects often obtain the finest healthcare possible for their Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy  Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
For Condition: recurrent breast cancer,stage 3 breast cancer,stage 4 breast cancer
Status: No longer recruiting
Sponsor(s): EORTC New Drug Development Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating women who have advanced or metastatic breast cancer that has not responded to previous chemotherapy.
Details: OBJECTIVES: I. Determine the therapeutic activity of oxaliplatin in patients with advanced or metastatic breast cancer following failure of anthracycline/taxane based chemotherapy. II. Determine objective response, duration of response, and time to progression in these patients when treated with this regimen. III. Determine the acute side effects of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive oxaliplatin IV over 2 hours on day 1. Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression and then every 3 months for survival. PROJECTED ACCRUAL: A total of 27-40 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed advanced or metastatic breast cancer - Bidimensionally measurable disease; At least one lesion at least 2 cm in one dimension by CT or MRI - Must have failed prior anthracycline/taxane based chemotherapy as defined by one of the following: Stage IV disease treated with anthracycline/taxane combination as first line therapy for advanced or metastatic disease; Stage IV disease treated with first line anthracycline therapy and second line taxane therapy for advanced or metastatic disease; Any adjuvant treatment other than anthracycline based therapy followed by anthracycline/taxane combination as first line therapy for advanced or metastatic disease; Any adjuvant therapy other than anthracycline based therapy followed by first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease; Adjuvant anthracycline based therapy followed by relapse after 6 months treated with anthracycline/taxane combination as first line therapy or first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease; Adjuvant anthracycline based therapy followed by relapse within 6 months treated with first line taxane based therapy for advanced or metastatic disease - Disease progression within 6 months of last taxane based chemotherapy - No brain metastases - Hormonal receptor status: Not specified --Prior/Concurrent Therapy-- - Biologic therapy: No prior high dose chemotherapy with hematopoietic rescue; No concurrent immunotherapy; No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) for prevention of neutropenia - Chemotherapy: See Disease Characteristics; At least 4 weeks since prior chemotherapy; At least 1 prior taxane based chemotherapy for advanced or metastatic disease; No prior high dose chemotherapy with hematopoietic rescue; No prior platinum based chemotherapy; No prior taxane chemotherapy other than docetaxel or paclitaxel; No prior adjuvant or neoadjuvant therapy with taxane/anthracycline based combination chemotherapy - Endocrine therapy: No concurrent steroids except in case of allergy prevention, emesis prophylaxis, or long term treatment for more than 3 months prior to study; No concurrent hormonal anticancer therapy - Radiotherapy: No prior radiotherapy to study site unless evidence of disease progression; Concurrent local radiotherapy allowed for pain relief - Surgery: At least 4 weeks since prior major surgery - Other: At least 4 weeks since prior anticancer and/or investigational drug; No concurrent bisphosphonates unless started at least 2 months prior to study; No other concurrent anticancer therapy; No other concurrent experimental drugs --Patient Characteristics-- - Age: 18 and over - Sex: Female - Menopausal status: Not specified - Performance status: WHO 0-2 - Life expectancy: At least 3 months - Hematopoietic: Absolute neutrophil count greater than 2,000/mm3; Platelet count greater than 100,000/mm3 - Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN); Alkaline phosphatase and transaminases no greater than 2.5 times ULN (no greater than 5 times ULN in case of liver metastases) - Renal: Creatinine less than 1.25 times ULN - Cardiovascular: LVEF at least 50% if prior total dose of doxorubicin 550 mg/m2 or greater, epirubicin 900 mg/m2 or greater, or pirarubicin 700 mg/m2 or greater; No prior or active congestive heart failure, myocardial infarction, or angina; No uncontrolled hypertension or arrhythmia - Other: No unstable systemic disease; No active infection; No grade 2 or greater peripheral neuropathy; No psychological, familial, sociological, or geographical condition that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PierreFumoleau, Study Chair, EORTC New Drug Development Group
Kaiser Franz Josef Hospital
Vienna (Wien), , A-1100
Austria
Institute of Oncology, Ljubljana
LJUBLJANA, , Sl-1000
Slovenia
Beatson Oncology Centre
Glasgow, Scotland, G11 6NT
United Kingdom
Rambam Medical Center
Haifa, , 31096
Israel
Universitats-Krankenhaus Eppendorf
Hamburg, , D-20246
Germany
CRLCC Nantes - Atlantique
Nantes-Saint Herblain, , 44805
France
CHU de la Timone
Marseille, , 13385
France
Institut Jules Bordet
Brussels (Bruxelles), , 1000
Belgium
Schneider Children's Medical Center of Israel
Petah-Tikva, , 49202
Israel
Centre Eugene Marquis
Rennes, , 35064
France
Additional Information:
Study ID Numbers: CDR0000068135; EORTC-16001
Study Start Date: May 2000
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006121
Other Recurrent Breast Cancer Studies:
1. Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
2. Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
3. Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
4. Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
Related Studies:
Other recurrent breast cancer Clinical Trials
Other Clinical Trials
Other Marseille Clinical Trials
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
|
|
|
|
|
|
|
|
